Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
23.7 USD | +0.72% | +1.50% | -15.51% |
Apr. 15 | Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating | MT |
Apr. 12 | Pharvaris Files Mixed Shelf | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.51% | 1.27B | |
+25.66% | 48.09B | |
+48.09% | 40.62B | |
-1.72% | 40.43B | |
-6.20% | 28.36B | |
+7.93% | 24.89B | |
-19.72% | 19.01B | |
+29.28% | 12.09B | |
+0.21% | 11.88B | |
+0.76% | 11.8B |
- Stock Market
- Equities
- PHVS Stock
- News Pharvaris N.V.
- Pharvaris' Phase 2 Study of Deucrictibant Meets Primary Endpoint; Prices $300 Million Offering; Shares Jump 42% Pre-Bell